Mucosis creates SAB
This article was originally published in Scrip
Dutch biotech company Mucosis, which is developing mucosal vaccines, has formed a new scientific advisory board. The members are: Dr Jiri Mestecky, who is with the department of microbiology and medicine at the University of Alabama; Dr Willem van Eden from the department of infectious diseases and immunology of the veterinary faculty at Utrecht University in the Netherlands; and Dr Peter Openshaw, a professor of experimental medicine and director of the Centre for Respiratory Infection at the National Heath and Lung Institute at Imperial College, London.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.